Jeffrey S Dome

List of Publications by Year
in descending order

148 papers	7,458 citations	36271 51 h-index	60583 81 g-index
159 all docs	159 docs citations	159 times ranked	6124 citing authors

#	Article	IF	Citations
1	Treatment of Anaplastic Histology Wilms' Tumor: Results From the Fifth National Wilms' Tumor Study. Journal of Clinical Oncology, 2006, 24, 2352-2358.	0.8	290
2	Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration. Journal of Clinical Oncology, 2015, 33, 2999-3007.	0.8	281
3	A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor. Nature Genetics, 2017, 49, 1487-1494.	9.4	255
4	Recurrent DGCR8, DROSHA, and SIX Homeodomain Mutations in Favorable Histology Wilms Tumors. Cancer Cell, 2015, 27, 286-297.	7.7	244
5	Rhabdoid Tumor of the Kidney in The National Wilms' Tumor Study: Age at Diagnosis As a Prognostic Factor. Journal of Clinical Oncology, 2005, 23, 7641-7645.	0.8	227
6	Current Therapy for Wilmsâ€™ Tumor. Oncologist, 2005, 10, 815-826.	1.9	179
7	Management of Wilms' tumour: current practice and future goals. Lancet Oncology, The, 2004, 5, 37-46.	5.1	167
8	Hypomethylation and hypermethylation of DNA in Wilms tumors. Oncogene, 2002, 21, 6694-6702.	2.6	165
9	DICER1 mutations in childhood cystic nephroma and its relationship to DICER1-renal sarcoma. Modern Pathology, 2014, 27, 1267-1280.	2.9	153
10	Local lymph node involvement does not predict poor outcome in pediatric renal cell carcinoma. Cancer, 2004, 101, 1575-1583.	2.0	152
11	Wilms tumour: prognostic factors, staging, therapy and late effects. Pediatric Radiology, 2008, 38, 2-17.	1.1	140
12	Children's Oncology Group's 2013 blueprint for research: Renal tumors. Pediatric Blood and Cancer, 2013, 60, 994-1000.	0.8	140
13	Genomic Loss of Tumor Suppressor miRNA-204 Promotes Cancer Cell Migration and Invasion by Activating AKT/mTOR/Rac1 Signaling and Actin Reorganization. PLoS ONE, 2012, 7, e52397.	1.1	138
14	Recent advances in Wilms tumor genetics. Current Opinion in Pediatrics, 2002, 14, 5-11.	1.0	135
15	Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clinical Cancer Research, 2003, 9, 5442-53.	3.2	135
16	The feasibility and outcome of nephronâ€sparing surgery for children with bilateral Wilms tumor. Cancer, 2008, 112, 2060-2070.	2.0	125
17	Risk Stratification for Wilms Tumor: Current Approach and Future Directions. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 215-223.	1.8	124
18	Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase. British Journal of Haematology, 2003, 120, 846-849.	1.2	118

#	Article	IF	Citations
19	Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Childrenâ€™s Oncology Group. Journal of Clinical Oncology, 2016, 34, 3189-3194.	0.8	117
20	Molecular Characterization of the Pediatric Preclinical Testing Panel. Clinical Cancer Research, 2008, 14, 4572-4583.	3.2	116
21	Clinically Relevant Subsets Identified by Gene Expression Patterns Support a Revised Ontogenic Model of Wilms Tumor: A Children's Oncology Group Study. Neoplasia, 2012, 14, 742-IN21.	2.3	105
22	Improved Survival for Patients With Recurrent Wilms Tumor: The Experience at St. Jude Children's Research Hospital. Journal of Pediatric Hematology/Oncology, 2002, 24, 192-198.	0.3	104
23	Characterization of adolescent and pediatric renal cell carcinoma: A report from the Children's Oncology Group study AREN03B2. Cancer, 2015, 121, 2457-2464.	2.0	92
24	Telomerase Expression Predicts Unfavorable Outcome in Osteosarcoma. Journal of Clinical Oncology, 2004, 22, 3790-3797.	0.8	90
25	Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Childrenâ€™s Oncology Group AREN0533 Study. Journal of Clinical Oncology, 2018, 36, 1564-1570.	0.8	87
26	Lymph node involvement in Wilms tumor: results from National Wilms Tumor Studies 4 and 5. Journal of Pediatric Surgery, 2012, 47, 700-706.	0.8	83
27	Gain of 1q is associated with inferior eventâ€free and overall survival in patients with favorable histology Wilms tumor: A report from the Children's Oncology Group. Cancer, 2013, 119, 3887-3894.	2.0	82
28	TP53 Mutational Status Is a Potential Marker for Risk Stratification in Wilms Tumour with Diffuse Anaplasia. PLoS ONE, 2014, 9, e109924.	1.1	82
29	Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group. Clinical Cancer Research, 2016, 22, 5582-5591.	3.2	82
30	Satellite DNA hypomethylation in karyotyped Wilms tumors. Cancer Genetics and Cytogenetics, 2003, 141, 97-105.	1.0	81
31	Clinicopathologic Findings Predictive of Relapse in Children With Stage III Favorable-Histology Wilms Tumor. Journal of Clinical Oncology, 2013, 31, 1196-1201.	0.8	78
32	Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Childrenâ€™s Oncology Group Study AREN0532. Journal of Clinical Oncology, 2018, 36, 254-261.	0.8	78
33	Treatment of relapsed Wilms tumors: lessons learned. Expert Review of Anticancer Therapy, 2009, 9, 1807-1815.	1.1	77
34	Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor. Annals of Surgery, 2017, 265, 835-840.	2.1	77
35	WT1 Mutation and 11P15 Loss of Heterozygosity Predict Relapse in Very Low-Risk Wilms Tumors Treated With Surgery Alone: A Children's Oncology Group Study. Journal of Clinical Oncology, 2011, 29, 698-703.	0.8	75
36	A genome-wide association study identifies susceptibility loci for Wilms tumor. Nature Genetics, 2012, 44, 681-684.	9.4	72

#	Article	IF	Citations
37	The classification of pediatric and young adult renal cell carcinomas registered on the children's oncology group (COG) protocol AREN03B2 after focused genetic testing. Cancer, 2018, 124, 3381-3389.	2.0	72
38	Disappearance of the Telomere Dysfunction-Induced Stress Response in Fully Senescent Cells. Cancer Research, 2004, 64, 3748-3752.	0.4	71
39	Clinical significance of pulmonary nodules detected by CT and Not CXR in patients treated for favorable histology Wilms tumor on national Wilms tumor studiesâ€4 and â€5: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2012, 59, 631-635.	0.8	71
40	Cefixime Allows Greater Dose Escalation of Oral Irinotecan: A Phase I Study in Pediatric Patients With Refractory Solid Tumors. Journal of Clinical Oncology, 2006, 24, 563-570.	0.8	70
41	Evaluation of diagnostic performance of CT for detection of tumor thrombus in children with Wilms tumor: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2012, 58, 551-555.	0.8	65
42	MLLT1 YEATS domain mutations in clinically distinctive Favourable Histology Wilms tumours. Nature Communications, 2015, 6, 10013.	5.8	64
43	Primary nephrectomy and intraoperative tumor spill: Report from the Children's Oncology Group (COG) renal tumors committee. Journal of Pediatric Surgery, 2013, 48, 34-38.	0.8	62
44	High Telomerase RNA Expression Level Is an Adverse Prognostic Factor for Favorable-Histology Wilms' Tumor. Journal of Clinical Oncology, 2005, 23, 9138-9145.	0.8	61
45	Topotecan Is Active Against Wilmsâ€™ Tumor: Results of a Multi-Institutional Phase II Study. Journal of Clinical Oncology, 2007, 25, 3130-3136.	0.8	60
46	Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clinical Genitourinary Cancer, 2019, 17, 1-6.	0.9	60
47	Treatment of Metastatic Rhabdoid Tumor of the Kidney. Journal of Pediatric Hematology/Oncology, 2002, 24, 385-388.	0.3	59
48	Predicting Relapse in Favorable Histology Wilms Tumor Using Gene Expression Analysis: A Report from the Renal Tumor Committee of the Children's Oncology Group. Clinical Cancer Research, 2009, 15, 1770-1778.	3.2	59
49	Loss of Heterozygosity at 2q37 in Sporadic Wilms' Tumor: Putative Role for miR-562. Clinical Cancer Research, 2009, 15, 5985-5992.	3.2	56
50	Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multi-Tumor Associated Antigen Specific Cytotoxic T Lymphocytes: A Phase I Study. Journal of Clinical Oncology, 2019, 37, 2349-2359.	0.8	56
51	Molecular profiling reveals frequent gain of MYCN and anaplasiaâ€specific loss of 4q and 14q in wilms tumor. Genes Chromosomes and Cancer, 2011, 50, 982-995.	1.5	54
52	Telomerase Activity and Prognosis in Primary Breast Cancers. Journal of Clinical Oncology, 1999, 17, 3075-3081.	0.8	52
53	Amplification and Overexpression of CACNA1E Correlates with Relapse in Favorable Histology Wilms' Tumors. Clinical Cancer Research, 2006, 12, 7284-7293.	3.2	52
54	Overall Survival and Renal Function of Patients With Synchronous Bilateral Wilms Tumor Undergoing Surgery at a Single Institution. Annals of Surgery, 2015, 262, 570-576.	2.1	52

#	Article	IF	Citations
55	Subsets of Very Low Risk Wilms Tumor Show Distinctive Gene Expression, Histologic, and Clinical Features. Clinical Cancer Research, 2009, 15, 6800-6809.	3.2	51
56	Detection of Preoperative Wilms Tumor Rupture with CT: A Report from the Childrenâ€™s Oncology Group. Radiology, 2013, 266, 610-617.	3.6	51
57	Activity of Vincristine and Irinotecan in Diffuse Anaplastic Wilms Tumor and Therapy Outcomes of Stage II to IV Disease: Results of the Childrenâ€™s Oncology Group AREN0321 Study. Journal of Clinical Oncology, 2020, 38, 1558-1568.	0.8	50
58	Hepatic Metastasis at Diagnosis in Patients With Wilms Tumor is not an Independent Adverse Prognostic Factor for Stage IV Wilms Tumor. Annals of Surgery, 2009, 250, 642-648.	2.1	48
59	Blastemal Expression of Type I Insulin-Like Growth Factor Receptor in Wilms' Tumors Is Driven by Increased Copy Number and Correlates with Relapse. Cancer Research, 2006, 66, 11148-11155.	0.4	47
60	Complete Response of Recurrent Cellular Congenital Mesoblastic Nephroma to Chemotherapy. Journal of Pediatric Hematology/Oncology, 2002, 24, 478-481.	0.3	45
61	Comparison of diagnostic performance of CT and MRI for abdominal staging of pediatric renal tumors: a report from the Childrenâ€™s Oncology Group. Pediatric Radiology, 2015, 45, 166-172.	1.1	45
62	Results of Treatment for Patients With Multicentric or Bilaterally Predisposed Unilateral Wilms Tumor (AREN0534): A report from the Children's Oncology Group. Cancer, 2020, 126, 3516-3525.	2.0	45
63	Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Childrenâ€™s Oncology Group AREN0532 and AREN0533 Study Report. Journal of Clinical Oncology, 2019, 37, 2769-2777.	0.8	44
64	Treatment of recurrent clear cell sarcoma of the kidney with brain metastasis. Pediatric Blood and Cancer, 2008, 50, 246-249.	0.8	40
65	Outcome of patients with stage II/favorable histology wilms tumor with and without local tumor spill: A report from the National Wilms Tumor Study Group. Pediatric Blood and Cancer, 2014, 61, 134-139.	0.8	39
66	Surgical protocol violations in children with renal tumors provides an opportunity to improve pediatric cancer care: a report from the Children's Oncology Group. Pediatric Blood and Cancer, 2016, 63, 1905-1910.	0.8	39
67	Telomere Shortening Alters the Kinetics of the DNA Damage Response after Ionizing Radiation in Human Cells. Cancer Prevention Research, 2011, 4, 1973-1981.	0.7	37
68	Impact of Surveillance Imaging Modality on Survival After Recurrence in Patients With Favorable-Histology Wilms Tumor: A Report From the Childrenâ€™s Oncology Group. Journal of Clinical Oncology, 2018, 36, 3396-3403.	0.8	37
69	New approaches to risk stratification for Wilms tumor. Current Opinion in Pediatrics, 2021, 33, 40-48.	1.0	36
70	Incorporation of fluorescently labeled actin and tropomyosin into muscle cells. Cell Differentiation, 1988, 23, 37-52.	1.3	35
71	Treatment of Refractory Osteosarcoma With Fractionated Cyclophosphamide and Etoposide. Journal of Pediatric Hematology/Oncology, 2002, 24, 250-255.	0.3	35
72	A unique subset of low-risk Wilms tumors is characterized by loss of function of TRIM28 (KAP1), a gene critical in early renal development: A Childrenâ€™s Oncology Group study. PLoS ONE, 2018, 13, e0208936.	1.1	35

#	Article	IF	Citations
73	Pediatric cystic nephromas: distinctive features and frequent DICER1 mutations. Human Pathology, 2016, 48, 81-87.	1.1	33
74	Aberrant activation, nuclear localization, and phosphorylation of yes-associated protein-1 in the embryonic kidney and Wilms tumor. Pediatric Blood and Cancer, 2014, 61, 198-205.	0.8	32
75	Treatment of stage I anaplastic Wilms' tumour: a report from the Children's Oncology Group AREN0321 study. European Journal of Cancer, 2019, 118, 58-66.	1.3	32
76	Clinical and biologic significance of nuclear unrest in Wilms tumor. Cancer, 2003, 97, 2318-2326.	2.0	30
77	Margin status and tumor recurrence after nephron-sparing surgery for bilateral Wilms tumor. Journal of Pediatric Surgery, 2013, 48, 1481-1485.	0.8	30
78	Repeat nephron-sparing surgery for children with bilateral Wilms tumor. Journal of Pediatric Surgery, 2014, 49, 149-153.	0.8	30
79	Imaging Characteristics of Nephrogenic Rests Versus Small Wilms Tumors: A Report From the Children's Oncology Group Study AREN03B2. American Journal of Roentgenology, 2020, 214, 987-994.	1.0	28
80	Forty-five patient-derived xenografts capture the clinical and biological heterogeneity of Wilms tumor. Nature Communications, 2019, 10, 5806.	5.8	27
81	Treatment of Stage IV Malignant Rhabdoid Tumor of the Kidney (MRTK) With ICE and VDCy. Journal of Pediatric Hematology/Oncology, 2006, 28, 286-289.	0.3	26
82	Is adrenalectomy necessary during unilateral nephrectomy for Wilms Tumor? A report from the Childrenâ€™s Oncology Group. Journal of Pediatric Surgery, 2013, 48, 1598-1603.	0.8	26
83	Impact of the First Generation of Childrenâ€™s Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 978-985.	2.3	26
84	The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma. Cancer Biology and Therapy, 2015, 16, 949-957.	1.5	24
85	Strategy for management of retroperitoneal tumors with caval tumor thrombus. Journal of Pediatric Surgery, 2011, 46, 2065-2070.	0.8	23
86	Current and Emerging Chemotherapy Treatment Strategies for Wilms Tumor in North America. Paediatric Drugs, 2008, 10, 115-124.	1.3	22
87	Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilmsâ€™ tumor. JCI Insight, 2019, 4, .	2.3	21
88	Outcome analysis of stage I epithelialâ€predominant favorableâ€histology Wilms tumors: A report from Children's Oncology Group study AREN03B2. Cancer, 2020, 126, 2866-2871.	2.0	20
89	ELR+-CXC Chemokines and Their Receptors in Early Metanephric Development. Journal of the American Society of Nephrology: JASN, 2007, 18, 2359-2370.	3.0	19
90	Delineation of a 1Mb breakpoint region at 1p13 in Wilms tumors by fine-tiling oligonucleotide array CGH. Genes Chromosomes and Cancer, 2007, 46, 607-615.	1.5	19

#	Article	IF	Citations
91	A prospective study of pediatric and adolescent renal cell carcinoma: A report from the Children's Oncology Group AREN0321 study. Cancer, 2020, 126, 5156-5164.	2.0	19
92	Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT. Blood Advances, 2022, 6, 2520-2534.	2.5	19
93	Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533. Journal of Clinical Oncology, 2022, 40, 3047-3056.	0.8	19
94	Telomere Biology of Pediatric Cancer. Cancer Investigation, 2007, 25, 197-208.	0.6	17
95	Imaging of renal medullary carcinoma in children and young adults: a report from the Childrenâ€™s Oncology Group. Pediatric Radiology, 2017, 47, 1615-1621.	1.1	17
96	ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcomaâ€”A Children's Oncology Group study. Cancer, 2020, 126, 5303-5310.	2.0	17
97	Omission of lung radiation in patients with stage IV favorable histology Wilms Tumor (FHWT) showing complete lung nodule response after chemotherapy: A report from Childrenâ€™s Oncology Group study AREN0533.. Journal of Clinical Oncology, 2015, 33, 10011-10011.	0.8	17
98	Treatment of stage IV favorable histology Wilms tumor with incomplete lung metastasis response after chemotherapy: A report from Childrenâ€™s Oncology Group study AREN0533.. Journal of Clinical Oncology, 2014, 32, 10001-10001.	0.8	16
99	Significance of pleural effusion in neuroblastoma. Pediatric Blood and Cancer, 2007, 49, 906-908.	0.8	15
100	Reopening Schools Safely: The Case for Collaboration, Constructive Disruption of Pre-Coronavirus 2019 Expectations, and Creative Solutions. Journal of Pediatrics, 2020, 223, 183-185.	0.9	15
101	Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor. Cancer Genetics, 2014, 207, 403-411.	0.2	13
102	Retroperitoneal lymph node dissection for pediatric renal cell carcinoma. Pediatric Blood and Cancer, 2009, 52, 430-430.	0.8	12
103	Outcome of Wilms tumor patients with bone metastasis enrolled on National Wilms Tumor Studies 1â€5: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2019, 66, e27430.	0.8	12
104	Targeting the HIF-1Î±-IGFBP2 axis therapeutically reduces IGF1-AKT signaling and blocks the growth and metastasis of relapsed anaplastic Wilms tumor. Oncogene, 2021, 40, 4809-4819.	2.6	12
105	A phase 2 study of vincristine and irinotecan in metastatic diffuse anaplastic Wilms tumor: Results from the Childrenâ€™s Oncology Group AREN0321 study.. Journal of Clinical Oncology, 2014, 32, 10032-10032.	0.8	12
106	Comprehensive renal function evaluation in patients treated for synchronous bilateral Wilms tumor. Journal of Pediatric Surgery, 2017, 52, 98-103.	0.8	11
107	Anthropomorphic measurements and eventâ€free survival in patients with favorable histology Wilms tumor: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2009, 52, 254-258.	0.8	10
108	Significance of pleural effusion at diagnosis of Wilms tumor. Pediatric Blood and Cancer, 2004, 42, 145-148.	0.8	9

#	Article	IF	Citations
109	Barriers to the Enrollment of Children in the Children's Oncology Group Study of Very Low Risk Wilms Tumor. Journal of Pediatric Hematology/Oncology, 2011, 33, 521-523.	0.3	8
110	Real-time central review: A report of the first 3,000 patients enrolled on the Childrenâ€™s Oncology Group Renal Tumor Biology and Risk Stratification protocol AREN03B2.. Journal of Clinical Oncology, 2014, 32, 10000-10000.	0.8	8
111	Kidney Preservation and Wilms Tumor Development in Children with Diffuse Hyperplastic Perilobar Nephroblastomatosis: A Report from the Childrenâ€™s Oncology Group Study AREN0534. Annals of Surgical Oncology, 2022, 29, 3252-3261.	0.7	8
112	Adjuvant therapy in pediatric patients with completely resected renal cell carcinoma. Pediatric Blood and Cancer, 2006, 46, 527-527.	0.8	7
113	Pediatric Solid Tumors. , 2020, , 1703-1747.e11.		7
114	Estimated SARS-CoV-2 Seroprevalence in Healthy Children and Those with Chronic Illnesses in the Washington Metropolitan Area as of October 2020. Pediatric Infectious Disease Journal, 2021, 40, e272-e274.	1.1	7
115	Feasibility of using CT volume as a predictor of specimen weight in a subgroup of patients with low risk Wilms tumors registered on COG Study AREN03B2: Implications for central venous catheter placement. Journal of Pediatric Urology, 2014, 10, 969-973.	0.6	6
116	Inflammatory myofibroblastic tumor as a second neoplasm after Wilms tumor. Pediatric Blood and Cancer, 2015, 62, 1075-1077.	0.8	6
117	Outcome of patients with intracranial relapse enrolled on national Wilms Tumor Study Group clinical trials. Pediatric Blood and Cancer, 2017, 64, e26406.	0.8	6
118	Outcomes based on histopathologic response to preoperative chemotherapy in children with bilateral Wilms tumor: A prospective study (COG AREN0534). Cancer, 2022, 128, 2493-2503.	2.0	6
119	Three molecular determinants of malignant conversion and their potential as therapeutic targets. Current Opinion in Oncology, 1999, 11, 58.	1.1	5
120	White paper: Oncoâ€fertility in pediatric patients with Wilms tumor. International Journal of Cancer, 2022, , .	2.3	5
121	Revisiting the Threshold for Cancer Genetics Referral in Patients With Wilms Tumor. Journal of Clinical Oncology, 2022, 40, 1853-1860.	0.8	5
122	Summary of COVIDâ€19 clinical practice adjustments across select institutions. Pediatric Blood and Cancer, 2020, 67, e28411.	0.8	4
123	BRAF V600E-mutated metastatic pediatric Wilms tumor with complete response to targeted RAF/MEK inhibition. Journal of Physical Education and Sports Management, 2020, 6, a004820.	0.5	4
124	A prospective study of pediatric renal cell carcinoma: A report from the Childrenâ€™s Oncology Group study AREN0321.. Journal of Clinical Oncology, 2018, 36, 10516-10516.	0.8	4
125	Pharmacogenetic and clinical predictors of ondansetron failure in a diverse pediatric oncology population. Supportive Care in Cancer, 2022, 30, 3513-3520.	1.0	4
126	Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors. Pediatric Blood and Cancer, 2021, 68, e29282.	0.8	3

#	Article	IF	Citations
127	Clinical outcome and biological predictors of relapse following nephrectomy only for very low risk Wilms tumor (VLR WT): A report from Childrenâ€™s Oncology Group AREN0532.. Journal of Clinical Oncology, 2015, 33, 10023-10023.	0.8	3
128	Intraatrial and intracaval Wilms' tumor. Journal of Pediatric Surgery, 2001, 36, 1869-1871.	0.8	2
129	Breast cancer in Wilms tumor survivors: New insights into primary and secondary prevention. Cancer, 2014, 120, 3598-3601.	2.0	2
130	Outcome and prognostic factors in stage III favorable histology Wilms tumor (FHWT): A report from the Childrenâ€™s Oncology Group (COG) study AREN0532.. Journal of Clinical Oncology, 2015, 33, 10010-10010.	0.8	2
131	Outcome of Donor-Derived Tumor Associated Antigen-Specific T Cell Therapy in Patients with High-Risk or Relapsed Acute Leukemia Post Allogeneic BMT. Blood, 2021, 138, 2828-2828.	0.6	2
132	Reply to D.M. Green. Journal of Clinical Oncology, 2018, 36, 3179-3181.	0.8	1
133	Wilms Tumor-Nephroblastoma. , 2019, , 11-29.		1
134	Reply to D.M. Green. Journal of Clinical Oncology, 2020, 38, 773-774.	0.8	1
135	Recurrent Respiratory Papillomatosis With Complete Response to Systemic Bevacizumab Therapy. Ear, Nose and Throat Journal, 2024, 103, 100-101.	0.4	1
136	Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.. Journal of Clinical Oncology, 2014, 32, 10052-10052.	0.8	1
137	ASO Video Abstract: Kidney Preservation and Wilms Tumor Development in Children with Diffuse Hyperplastic Perilobar Nephroblastomatosisâ€”A Report from the Childrenâ€™s Oncology Group Study AREN0534. Annals of Surgical Oncology, 2022, , 1.	0.7	1
138	Reply to B. Royer-Pokora et al. Journal of Clinical Oncology, 2011, 29, e487-e488.	0.8	0
139	Reply to Wilms tumor and breast cancer. Cancer, 2015, 121, 2100-2101.	2.0	0
140	Reply to B. Zhang et al. Journal of Clinical Oncology, 2018, 36, 1454-1455.	0.8	0
141	Reply to L. Xie et al. Journal of Clinical Oncology, 2019, 37, 1264-1265.	0.8	0
142	Wilms Tumor. , 2021, , 139-162.		0
143	Prognostic implications of gain of 1q in favorable histology Wilms tumor: A report from the Childrenâ€™s Oncology Group.. Journal of Clinical Oncology, 2013, 31, 10014-10014.	0.8	0
144	Safety and feasibility of magnetic resonance-guided high intensity focused ultrasound (MR-HIFU) for the ablation of relapsed or refractory pediatric solid tumors.. Journal of Clinical Oncology, 2016, 34, TPS10588-TPS10588.	0.8	0

#	Article	IF	Citations
145	Renal tumors. , 2022, , 525-540.		0
146	414â€...Enhancing T cell therapy for patients with relapsed/refractory Wilms tumor. , 2020, , .		0
147	Authorsâ€™ Reply to the Letter to the Editor by Daniel M. Green. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, xlvii-xlviii.	2.3	0
148	MP17-16â€ƒLONG-TERM OUTCOMES FOR PATIENTS WITH ANAPLASTIC BILATERAL WILMS TUMORS ENROLLED ON COG AREN0534. Journal of Urology, 2022, 207, .	0.2	0